Urinary Tract Treatments LTD

Back To Life

The Problem –Lingering Urinary tract disorders

Urinary tract Disorders affect over 60% of individuals throughout their lifetime. an

estimate for 2018 was that >2.5 billion women and men were affected by at least

one urinary diseases - including Cancer, Bacterial Infections, Incontinence,

Inflammations and more.

Some of the disorders are life-threatening, some of them are painful and seriously

reduce quality of life for long durations of time.

Most medications have non-optimal bioavailability due to ineffective delivery:

•Oral drugs have poor absorption in the bladder.

•Topical drugs are washed out of the bladder shortly after instillation.

UTT will dramatically enhance the efficacy of bladder medications by

providing solutions for prolonged topical exposure to the bladder tissue

Urinary tract Disorders

Urinary tract inflammation

incontinence

Overactive Bladder –OAB

Interstitial Cystitis –IC

Bladder Cancer

Prostate Cancer

Our Solutions –for Lingering Urinary tract Disorders

UTT Ltd. is offering 3 proprietary innovations technologies for fast relief of urinary tract

disorders:

1. A sponge for converting drugs to prolonged topical release application

2. A non-surgical chemo-ablation treatment for prostate cancer

3. An incontinence-management magnetic device

UTT objective is to offer:

A paradigm change in topical drug treatments.

A 1st dignified incontinence-control device

The Problem –Inflammations

Urinary tract infection (UTI), Interstitial Cystitis (IC) and Overactive Bladder (OAB)

are primarily due to bacterial infection of the urinary tract. Symptoms include

frequent and persistent urge to urinate, burning sensation, and lower abdominal

pain. Complications may include chronic pain, abscesses, sepsis - even renal failure.

Bladder Infections affect, in common, over 60% of women and over 20% of men all

over the world . They are treated by antibiotics ( with or without local hormone

replacements): orally, for a short course - in simple cases, or IV and longer course -

for complicated cases.

Over 50% world wide population suffers from urinary tract infections.

Low bioavailability limits the effect of systemic antibiotics.

Urinary Incontinence (UI) combines several types of mixed

disorders that may cause urge and/or stress to void and

involuntary urine escape. UI may be caused by a weakened

bladder support tissue, weak urethral sphincter or damage to the

nerve system. Lifestyle and behavioral factors (smoking, obesity,

etc.) may contribute to symptoms’severity.

Incontinence issues when coughing, sneezing or exercising are

very common –affecting up to 75%of women > 65 years.

Between absorbent pads and surgery –UI is mainly treated by

medicines with unpleasant side effects and limited efficacy.

The Problem -Urinary Incontinence

Urinary Incontinence is a wide-spread disorder. Current treatments

leave patients with discomfort and social distancing.

Progression is the problem!

BC is life threatening when it

becomes muscle invasive.

Recurrence is the problem!

The risk of progression, the

adverse effects and the costs -

all grow with each treatment

The Problem - Bladder Cancer

It can amount to

two critical issues:

Bladder Cancer (BC) affects 800,000 patients in the USA only , 80% are

males, 80% are smokers - causing 17,000 deaths/yr. Most tumors grow on

the bladder inner layer. Those that grow into the deeper bladder layers

may progress to invade the bladder wall and are harder to treat.

Diagnosed tumors are surgically removed (endoscopic resection) and then

treated with cycles of topical drugs, to prevent cancer progression.

Alternatively, cycles of intravesical chemotherapy can remove all tumors.

Invasive tumors may be treated with chemotherapy and radiation after

resection. In most cases partial or total removal of the bladder (cystectomy)

are necessary and require solutions for urine passage.

Prostate cancer is a male-only cancer, with annual ~300,000 new cases

in the USA, with >50% of patients over 65 years. It is the 2nd leading

deadly cancer in the US.

Symptoms include urination trouble, blood in urine or semen, bone pain

and fever.

When diagnosed early, prostate cancer is mostly local or regional and is

highly curable. If tumors spread beyond the prostate, survival rates fall

(5-yr. survival is reduced to 1 in 3 for distant spread).

Primary therapy is a complete surgical removal of the prostate, or

radiation therapy. Both treatments may damage nearby organs and

cause infections, incontinence, erectile dysfunction and impotence.

The Problem - Prostate Cancer

The two main prostate cancer problems:

•Older age of most patients;

•Side effects of surgical and radiation treatments of the prostate

Current Treatment - Urinary Incontinence

Downside:

Medication and topical treatment have a

small % yield, take longer to treat, and aren't

very effective. Side effects include dry mouth,

constipation, blurred vision, dizziness,

confusion , and nephrotoxicity

Urethral inserts are temporary and need to

be removed in order to urinate

Surgery is invasive and affects the quality of

life

Diapers can cause discomfort and shame

Standard therapy:

Medication

(Anticholinergics, Mirabegron, etc.)

Topical

(Cream, ring, pessary, or patch)

Urethral insert

Surgery

Diapers, pads, and absorbent

underwear

Our Solution –A drug retention sponge

UTT’s proprietary sponge enables the topical use of known drugs for fast and long term

relief of urinary diseases –such as inflammations, incontinence and cancer.

UTT’s biodegradable sponge is inserted via a catheter into the bladder, and expands

there. A target drug is then inserted and is absorbed by the sponge - for prolonged

retention that greatly increases the clinical efficacy. The sponge is biodegradable and is

naturally evacuated after several days.

This novel treatment modality enables the use of potent drugs

while avoiding systemic side effects. It is adaptable for the

treatment of bladder cancer (using chemotherapy), urinary

infection using antibiotics, Urinary incontinence using

antidepressants (to relax muscles), antimuscarinics (to dry) or

mirabegron (to desensitize).

Studies show early indication that Botox can similarly be used for

denervation of voiding signals and stop leakage.

Our Solution –Urinary Leakage-Control Device

UTT Ltd patented a revolutionary leakage-control device (ULC) –a magnetic

floating buoy that is inserted into the bladder and is compressed against the

bladder sphincter to provide a urine leakage barrier. The ULC is pulled by a

magnetic pad, worn in the underpants. As the underpants are naturally

removed, the buoy floats and voiding occurs naturally. The buoy

compression level is easily adjustable via the magnetic pad.

The device is comfortable, minimally invasive, reversible, and adaptable to

the specific anatomy and condition.

The ULC will greatly improve the quality of life for millions of incontinent

women and reduce the costs of incontinence.

No more

pads or

stains

Our Solution - Bladder Cancer

The UTT novel sponge enables chemo-ablation of bladder

tumors by direct, prolonged exposure of the bladder tissue to

chemotherapy.

Chemoablation was already proven as an alternative to

surgical resection of Non-Muscle Invasive Bladder Cancer

(NMIBC). The UTT sponge will provide a longer drug dwell

time that will enhance efficacy and may enable eradication of

in-growing tumors (CIS) –that are the main cause for cancer

progression.

Longer exposure time replaces the need for higher drug

dosage, thus the known systemic and topical adverse effects

of chemotherapy will be minimal and patient’s compliance

will be high.

Our Solution - Prostate Cancer

UTT intends to treat local prostate tumors non-surgically by using slow-release

chemotherapy for chemo-ablation. The chemotherapy agent will be dissolved

into a proprietary liquid gel and then injected into the prostate. The gel will

release the chemotherapy agent continuously over the duration of several

days. The direct exposure of the prostate tumors to the chemotherapy gel will

eradicate the cancerous cells.

Eliminating the need for surgery and its risk of severe adverse events, may be

dramatic: Today the “watchful wait” strategy is common and prostate surgery

is delayed for as long as possible. With UTT’s Chemo-Gel –patients

compliance will be enhanced –probably saving lives.

UTT is offering 3 solutions for prolonged topical drug release:

1. UTT Sponge - enables the use of existing medications to topical delivery.

UTT will implement sponge-based topical drug treatments for bladder infections,

overactive bladder, urinary incontinence and bladder cancer

2. Chemo-Gel -injectable gel, loaded with chemotherapy for prolonged release.

UTT will implement the Chemo-Gel for a minimally-invasive, non-surgical treatment of

prostate cancer.

3. Leakage-Control Device (ULC) –an in-dwelling magnetic bladder buoy.

Floating and exerting pressure on the sphincter for incontinence control.

UTT Solutions for urinary tract disorders

UTT Markets

Market Size (@2030)

Billion $

11.4

2.3

1.2

7.5

inflammations Interstitial

cystitis

Overactive

bladder

Incontinence Bladder

Cancer

Prostate

Cancer

Inflammations

11.4 Billion

Interstitial cystitis

2.3 Billion

Overactive bladder

5 Billion

Incontinence

6 Billion

Bladder Cancer

1.2 Billion

Prostate Cancer

7.5 Billion

WW Prevalence/ Deaths

Aiming for fast success

Granted USA patent

US6589228B2

Patent

Application

July

2023

November

2023

Dec

2024

Jan

2024

May

2024

Sep

2024

Raising

Money

Product

development

Gel

POC Sponge

POC ULC

POC

1st in

Human

Public

Offering

Crowd

funding

$1.2 M

Raising

$300 K

3nd Patent

Application

2st Patent

Application

The Founders

Asher Holzer , Ph.D

president, Founder

Asher is a serial entrepreneur and a

senior executive in the medical

equipment industry. He has over 30

years of experience in founding,

leading, and taking several public

companies that have created and

marketed cutting-edge medical

technologies and solutions. Some of

his notable ventures include UroGen,

InspireMD, BioSig, and TheraCoat. He

holds a Ph.D. in nuclear physics from

the Hebrew University and has a

passion for innovation and excellence

in the healthcare field.

Eli Ben Haroosh

CEO, Founder, and Director

Eli is a seasoned executive and entrepreneur

with a proven track record of leading and

growing successful businesses in various

fields. He recently served as the President of

Vonetize, a stock-exchange company that

provides premium content and technology

solutions. Before that, he was the VP and

CEO of Premier –Dead Sea, a global leader

in skincare products. He oversaw sales in 74

countries and nearly 1000 sales points,

generating tens of millions of dollars a year.

Eli currently serves as the director of several

companies and as the president of Mariana

Inc., a company that focuses on cannabis

research and development.

The Advisory Board

Eng. Yosh Dollberg

Yosh is a founder and R&D manager of

UroGen Pharma, a biotech company

that develops novel solutions for rare

cancers and urologic diseases. He is an

expert in photoacoustic imaging, a

technique, and has co-authored a

publication on photoacoustic ocular

imaging. Yosh is also a co-founder of

Pontifax Group, a venture capital firm

that invests in healthcare startups

around the globe. He joined the UTT

team as he believes UTT can drastically

change the way bladder diseases and

cancers are treated.

Prof. Lior Nesher

M.D. Director

Lior is the Director of the Infectious

Disease Institute at Soroka University

Medical Center (SUMC), a 1,100-bed

referral hospital providing medical care for

over 1,000,000 people in the southern

part of Israel. Immunocompromised

patients, especially cancer and transplant

recipients, and antibiotic stewardship

systemic interventions lead the COVID-19

response at SUMC.

Prof. Nesher is a tenured faculty member

of the Faculty of Health Sciences, Ben-

Gurion University of the Negev, a member

of the European Society Clinical

Microbiology, Infectious Disease

(ESCMID), as well as an executive board

member of the ESCMID study group on

respiratory viruses (ESGREV).

Prof. David Margel,

M.D. PhD. MBA, Director

Dr. David Margel is a Professor of Surgery.

Dr. Margel is currently the Medical

Director of Raphael Hospital and founding

director of Men's Health. As a surgeon-

scientist, he founded the Rabin Medical

prostate cancer focal treatment program

and the male BRCA comprehensive

research unit and clinic.

Dr. Margel's research program, which

spans from bench to bedside, focuses on

the biology and genetics of urological

cancers and cardio-oncology.

He serves as the principal investigator for

multiple clinical trials evaluating novel

therapy technologies, genetics as well as

other aspects to provide better care and

less toxic treatments for patients.

The Team

Dr. Zeev Schmelzer

Patent Advisor

Patent attorney in the field of

mechanics, medical equipment,

biology and medicine, with over

13 years of experience in the field.

Gad Benett

Patent Advisor

Patent Attorney & Managing Partner at

Paulina Ben-Ami, Patent Attorneys

Paulina Ben-Ami is a boutique IP firm,

serving hundreds of clients both nationally

and internationally.

Before, Gad worked in business

development and product management for

innovative startups in Silicon Valley and

elsewhere. Before, Gad was a software

engineer.

Gad holds a Master’s degree in Software

Engineering from the University of Paris 2,

and an MBA from the McCombs School of

Business at the University of Texas at Austin.

Thank You!

Disease burden and long-term trends of urinary tract infections: A worldwide report

•Xiaorong Yang, 1 Hui Chen, 1 Yue Zheng, 2 Sifeng Qu, 3 Hao Wang,corresponding author 4 , 5 , * and Fan Yicorresponding author 5 , *

•Front Public Health. 2022; 10: 888205.Published online 2022 Jul 27. doi: 10.3389/fpubh.2022.888205, PMCID: PMC9363895, PMID:

35968451

National prevalence of IC/BPS in women and men utilizing veterans health administration data

Jennifer T. Anger,corresponding author 1 , * , † Kai B. Dallas, 2 , † Catherine Bresee, 3 Amanda M. De Hoedt, 4 Kamil E. Barbour, 5

Katherine J. Hoggatt, 6 Marc T. Goodman, 7 Jayoung Kim, 7 , 8 and Stephen J. Freedland 4 , 7 , 8

Front Pain Res (Lausanne). 2022; 3: 925834.Pub. online 2022 Aug 24. doi: 10.3389/fpain.2022.925834 PMCID: PMC9448885 PMID:

36093391

Definition & Facts of Interstitial Cystitis

National Institute of diabetes and Digestive and Kidney Diseases

The prevalence of urinary incontinence

I Milsom, M Gyhagen PMID: 30572737 DOI: 10.1080/13697137.2018.1543263 https://pubmed.ncbi.nlm.nih.gov/30572737/

Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and

bladder outlet obstruction

Debra E. Irwin,Zoe Kopp,Barnabie Agatep,Ian Milsom,Paul Abrams

First published: 13 January 2011 https://doi.org/10.1111/j.1464-410X.2010.09993